Degradation of dimethyl phthalate using a liquid phase plasma process with TiO2 photocatalysts.

The liquid phase plasma (LPP) method with a TiO2 photocatalyst and hydrogen peroxide was used to decompose dimethyl phthalate (DMP). As the applied voltage, pulse width, and frequency were increased, the rate of decomposition was increased and the decomposition rate was 63% for 180 min under plasma optimum conditions. The addition of TiO2 photocatalyst and hydrogen peroxide increased the DMP decomposition reaction rate, but an excess cause a decrease in decomposition rate due to a decrease in conductivity, blocking of ultraviolet light, and scavenger effect. When the TiO2 photocatalyst and hydrogen peroxide were used together, the decomposition reaction rate of DMP was greatly improved by using LPP single process alone. Also, when all the processes were used at the same time, the decomposition reaction rate was improved to about 2.8 times. DMP undergoes bond cleavage and ultimately decomposes into CO2 and H2O via dimethyl 4-hydroxyphthalate and methyl salicylates due to hydroxyl radicals and various active species generated by the LPP reaction.

Novel chimeric peptide with enhanced cell specificity and anti-inflammatory activity.

An antimicrobial peptide (AMP), Hn-Mc, was designed by combining the N-terminus of HPA3NT3 and the C-terminus of melittin. This chimeric AMP exhibited potent antibacterial activity with low minimal inhibitory concentrations (MICs), ranging from 1 to 2 µM against four drug-susceptible bacteria and ten drug-resistant bacteria. Moreover, the hemolysis and cytotoxicity was reduced significantly compared to those of the parent peptides, highlighting its high cell selectivity. The morphological changes in the giant unilamellar vesicles and bacterial cell surfaces caused by the Hn-Mc peptide suggested that it killed the microbial cells by damaging the membrane envelope. An in vivo study also demonstrated the antibacterial activity of the Hn-Mc peptide in a mouse model infected with drug-resistant bacteria. In addition, the chimeric peptide inhibited the expression of lipopolysaccharide (LPS)-induced cytokines in RAW 264.7 cells by preventing the interaction between LPS and Toll-like receptors. These results suggest that this chimeric peptide is an antimicrobial and anti-inflammatory candidate as a pharmaceutic agent.